Real-world outcomes of frontline polatuzumab-rchp and impact of frailty in older adults with diffuse large B-cell lymphomaVarun Iyengar, Pallawi Torka, Adrienne Nedved et al.|Blood|2025Cited by 1
ABCL-817: Real-World Outcomes of Frontline Polatuzumab and Impact of Frailty in Older Adults With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): A Multicenter StudyJessica Chicola, Pallawi Torka, Jomel Meeko Manzano et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0
POSTER: ABCL-817 Real-World Outcomes of Frontline Polatuzumab and Impact of Frailty in Older Adults With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): A Multicenter StudyJessica Chicola, Pallawi Torka, Jomel Meeko Manzano et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0
Performance Status Outperforms Comorbidities As Predictor of Survival after Bsabs for Large B cell LymphomaGeoffrey Shouse, Ayushi Chauhan, Jomel Meeko Manzano et al.|Transplantation and Cellular Therapy|2026Cited by 0
Outcomes of Bispecific Antibody Treatment of Double Hit Lymphoma, a Real-World Evidence (RWE) StudyGeoffrey Shouse, Gulrayz Ahmed, Jomel Meeko Manzano et al.|Transplantation and Cellular Therapy|2026Cited by 0